Literature DB >> 21447926

[Morphological analysis of bone dynamics and metabolic bone disease. Does bisphosphonate treatment cause severely suppressed bone turnover (SSBT) ?].

Naoki Kondo1, Takuya Yoda.   

Abstract

Bisphosphonates are anti-resorptive drug and increase both bone strength and toughness. However, their long term treatment oversuppresses bone turnover and promotes advanced glycation end-products in bone tissue, resulting in low bone quality. These conditions are called "severely suppressed bone turnover (SSBT) " , and can cause "atypical" , low-impact fractures of the femoral subtrochanteric or shaft. It is evident that bisphosphonates prevent fracture risk in vertebral body or femoral neck and improve quality of life in patients with osteoporosis, but clinicians, especially bone specialists, have to keep the associations between bisphosphonate use and SSBT in mind. Rational approach to atypical femoral subtrochanteric÷shaft fractures should be determined in near future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447926     DOI: CliCa1104583587

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  1 in total

1.  Importance and Difficulty of Differentiating BMA-induced AFF Prodromal Symptoms from Hormonal Therapy-related Femoral Pain.

Authors:  Shuji Ota; Toru Tokizaki; Masakazu Sugimoto; Ryosuke Ochiai; Terunobu Haruyama; Masashi Ishihara; Maika Natsume; Yoko Fukasawa; Takahiko Sakamoto; Shigeru Tanzawa; Ryo Usui; Takeshi Honda; Yasuko Ichikawa; Kiyotaka Watanabe; Hirotaka Kawano; Nobuhiko Seki
Journal:  Intern Med       Date:  2019-11-22       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.